Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Association of a functional NOS1 promoter repeat with Alzheimer's disease in the VITA cohort.

Authors: Reif, Andreas  Grünblatt, Edna  Herterich, Sabine  Wichart, Ildiko  Rainer, Michael K  Jungwirth, Susanne  Danielczyk, Walter  Deckert, Jürgen  Tragl, Karl-Heinz  Riederer, Peter  Fischer, Peter 
Citation: Reif A, etal., J Alzheimers Dis. 2011;23(2):327-33. doi: 10.3233/JAD-2010-101491.
Pubmed: (View Article at PubMed) PMID:21098972
DOI: Full-text: DOI:10.3233/JAD-2010-101491

NO synthase, type I (NOS-I) has been suggested to play a role in the etiology of Alzheimer's disease (AD). The gene encoding NOS-I harbors at least nine alternative first exons; in the promoter region of exon 1f, a polymorphic repeat (NOS1 ex1f-VNTR) has been described which influences gene expression and neuronal transcriptome. We have shown that short alleles of this repeat are associated with AD. Here, we sought to further explore this finding by investigating a longitudinal cohort sample from the Vienna-Transdanube-Aging (VITA) study consisting of 606 subjects enrolled at the age of 75 (of these, genotypes were available for 574 subjects) and followed up for 60 months. The ex1f-VNTR risk genotype was associated with AD in the total sample and at the second follow-up. Thus, either long alleles of NOS1 ex1f-VNTR are protective against disease or conversely, short alleles predispose to earlier onset of disease. As demonstrated, ex1f-VNTR interacted with the apolipoprotein E e4 risk allele (OR in the presence of both risk alleles 3.63; 95% CI: 1.45-9.12). These findings provide further evidence for an association of NOS1 with AD.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
CRRD Object Information
CRRD ID: 13824974
Created: 2018-11-09
Species: All species
Last Modified: 2018-11-09
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.